Indication intelligence, analysis and sector perception

The Biostage (BSTG) Chronicles: Questions continue without any responses

April 13, 2021 8:17am

Maintaining Sell

MINORITY PUBLIC shareholders are waiting, watching and weighing responses to MAINTAIN their RIGHTS.

Biostage (BSTG) closed down Monday -$0.08 to $1.17 with 3,631 shares traded after Friday’s flat at $1.25 with 260 shares traded, Thursday with 6 shares traded, Wednesday’s $1.25 with 967 shares traded and last Tuesday’s -$0.05 to $1.25 with 2008 shares traded

<read more>

Question#1: HOW many executives or management “team members” remain at the company? Is the website truthful and up-to-date regarding those WHO have left for other positions?

Question2: WHO is in charge of clinical and pre-clinical development?

Question#3: WHAT is behind the volatility and daily volume relationship and WHO is “propping” the share pricing (review the differences). Shouldn’t RSM US LLP review the relationship with DST Capital and Hong Yu, president of BSTG?

35 companies, 1 interpreter!

Insight, foresight and recommendation

What's Happening Today

17 min ago
RegMed Investors (RMi) Closing Bell: hammered

9 hours 8 min ago
RegMed Investors’ (RMi) pre-open: expectation versus reality

My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.

My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.

Do you have an opinion you would like to share with us? We would like to hear from you.

Please e-mail us at hwm@regmedinvestors.com.

Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors with past experience in sell-side analysis, buy-side management, corporate management and due diligence.

RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.

The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.

The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.